The two drugs were previously approved by the FDA for Type 2 diabetes treatment in adults in 2014 and 2015 respectively. However, since 2000, children with the condition have only had one available oral-treatment option: Metformin — until now.
“Compared to adults, children with Type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidly in children,” Michelle Carey, MD, director of therapeutic review for the FDA’s Division of Diabetes, Lipid Disorders, and Obesity said in a statement. “Today’s approvals provide much-needed additional treatment options for children with Type 2 diabetes.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
